Medicine
8 years ago

Breakthrough discovery: HCMV protein blocks HIV replication, offering new treatment hope.

AIDS
Human cytomegalovirus product UL44 downregulates the transactivation of HIV-1 long terminal repeat
M C Boccuni, Fabio Campanini, M. C. Battista, Giovanna Bergamini, Paola Dal Monte, Alessandro Ripalti, M.P. Landini

Paper Summary

Related papers

Theme background image
Medicine
8 years ago

Breakthrough discovery: HCMV protein blocks HIV replication, offering new treatment hope.

Cytomegalovirus
HIV/AIDS
Herpesviruses Management
1 view
Theme background image
Immunology and Microbiology
8 years ago

HIV Protein Unlocks Key to Inflammation Control in Cells.

Myocarditis
HIV/AIDS
RNA Processing
Theme background image
Medicine
8 years ago

NF-κB Identified as Key Player in Activating HIV Gene Expression

Cytomegalovirus
HIV/AIDS
Herpesviruses Management

Human cytomegalovirus (HCMV) protein UL44 can reduce the activation of HIV-1 long terminal repeat (LTR) by interfering with the action of HIV-1 Tat and HCMV IE1/IE2 proteins. The researchers found that UL44 does not affect the baseline activation of LTR, but it significantly decreases the activation when Tat, IE1/IE2, or both are present. This inhibition is dose-dependent and is located within the last 114 amino acids of UL44. This study shows that UL44 has a negative impact on the ability of HIV-1 LTR to be activated by Tat and IE1/IE2, either alone or together.